These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35525962)

  • 1. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
    Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
    J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
    Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
    J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
    Zhou J; Zhang C; Pan J; Chen L; Qi ST
    Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics in pediatric cystic craniopharyngioma.
    Massimi L; Martelli C; Caldarelli M; Castagnola M; Desiderio C
    Brain Pathol; 2017 May; 27(3):370-376. PubMed ID: 28414889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of integrated stress response protects against lipid-induced senescence in hypothalamic neural stem cells in adamantinomatous craniopharyngioma.
    Wang C; Zhang H; Fan J; Li Q; Guo R; Pan J; Liu Y; Peng J; Zhu Q; Feng Y; Wu C; Luo P; Qiu X; Shi J; Deng Y; Qi S; Liu Y
    Neuro Oncol; 2023 Apr; 25(4):720-732. PubMed ID: 36454228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
    Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
    Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
    Martinez-Barbera JP
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
    Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
    Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
    Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
    Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of craniopharyngioma cyst fluid on neurons and glial cells cultured from rat brain hypothalamus.
    Ghosh M; Das S; Rao KVLN; Pruthi N; Ramesh VJ; Raju TR; Sathyaprabha TN
    J Chem Neuroanat; 2018 Dec; 94():93-101. PubMed ID: 30339791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
    Hengartner AC; Prince E; Vijmasi T; Hankinson TC
    Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
    Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
    Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
    Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
    Front Immunol; 2022; 13():949509. PubMed ID: 36091021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
    Apps JR; Martinez-Barbera JP
    Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis.
    Zhang H; Wang C; Fan J; Zhu Q; Feng Y; Pan J; Peng J; Shi J; Qi S; Liu Y
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12795. PubMed ID: 35156226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma.
    Li W; Zhang Y; Zhuang Y; Chen R; Xiong Z; Li K; Liu F; Xu H; Li D; Peng J
    Neuroendocrinology; 2024; 114(10):934-949. PubMed ID: 38964285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma.
    Chen M; Zheng SH; Liu Y; Shi J; Qi ST
    J Neurol Sci; 2016 Jan; 360():49-54. PubMed ID: 26723972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid from Patients After Craniotomy with the Appearance of Interleukin-6 Storm Can Activate Microglia to Damage the Hypothalamic Neurons in Mice.
    Huang H; Liao X; Zhang A; Qiu B; Mei F; Liu F; Zeng K; Yang C; Ma H; Ding W; Qi S; Bao Y
    Mol Neurobiol; 2024 May; 61(5):2707-2718. PubMed ID: 37924484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.